Skip to main content

Table 2 Clinical and laboratory data of patients with liver cirrhosis and hepatocellular carcinoma

From: Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography–mass spectrometry

Characteristics

LC

HCC

P

AFP (ng/mL)

6.2 ± 15.8

507.8 ± 1565.9

< 0.001*

AFP ≥ 20 ng/mL

2 (6.67)

12 (37.5)

-

AFP ≥ 200 ng/mL

0 (0.0)

6 (18.8)

-

ALT (UI/mL)

35.4 ± 41.3

39.5 ± 43.2

0.698

AST (UI/mL)

37.3 ± 22.4

45.3 ± 43.0

0.746

ALP (U/L)

86.6 ± 51.6

119.2 ± 70.1

0.022*

GGT (U/L)

64.2 ± 98.2

108.1 ± 121.0

0.045*

Total bilirubin (mg/dL)

0.7 ± 0.3

1.1 ± 1.4

0.481

Albumin (g/dL)

4.7 ± 0.4

4.4 ± 0.8

0.117

Platelets (*1,000/mm3)

155.8 ± 89.5

156.0 ± 86.3

0.910

PT (seconds)

14.1 ± 2.1

13.2 ± 1.7

0.013*

Child-Pugh score

   

 A

30 (53.6)

26 (46.4)

0.030*

 B or C

0 (0.0)

6 (100.0)

Total cholesterol (mg/dL)

179.4 ± 38.1

172.8 ± 41.0

0.511

Tumor size (mm)

-

37.0 ± 23.0

-

BCLC stage

   

 0

-

5 (15.6)

-

 A

-

14 (43.8)

-

 B

-

10 (31.2)

-

 C

-

1 (3.1)

-

 D

-

2 (6.3)

-

  1. Results are presented as number and percentage for categorical variables and as mean value and standard deviation for continuous variables. LC liver cirrhosis, HCC hepatocellular carcinoma, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma glutamyl transpeptidase, PT prothrombin time, BCLC Barcelona-Clinic Liver Cancer. *Significant at 0.05